Login / Signup

Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.

Guru Subramanian Guru MurthyAniko SzaboMehdi HamadaniTimothy S FenskeNirav N Shah
Published in: The oncologist (2019)
This article evaluates contemporary outcomes for advanced-stage Hodgkin lymphoma (HL) in the U.S. using the Surveillance, Epidemiology, and End Results database. Although overall survival (OS) has improved in each 5-year period since 2000, the 3-year OS from 2010 to 2014 remains inadequate at 81.8% and is limited by patient demographics. New therapies are indicated to improve clinical outcomes in advanced-stage HL.
Keyphrases
  • hodgkin lymphoma
  • public health
  • risk factors
  • type diabetes
  • adverse drug
  • metabolic syndrome
  • skeletal muscle
  • insulin resistance
  • drug induced